← All Curanex Pharmaceuticals INC filings

Curanex Pharmaceuticals INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
CURX
Curanex Pharmaceuticals INC
10-Q: Curanex Pharmaceuticals Reports Q2 2026 Results, Faces Going Concern Doubt
Curanex Pharmaceuticals Inc. filed its Q2 2026 10-Q, detailing increased operating expenses and net losses, while highlighting ongoing R&D efforts and significant concerns regarding its ability to continue as a going concern.
NASDAQ
CURX
Curanex Pharmaceuticals INC
10-Q: Curanex Pharmaceuticals Q1 2026 Results and Pipeline Update
Curanex Pharmaceuticals reports Q1 2026 results, highlighting significant R&D investment and progress towards IND submission for Phyto-N, while addressing Nasdaq bid price concerns.
NASDAQ
CURX
Curanex Pharmaceuticals INC
10-Q: Curanex Q3 Loss Widens on R&D, Faces Nasdaq Delisting Risk
Curanex Pharmaceuticals reported a significantly increased net loss in Q3 2025 due to substantial R&D investments following its IPO, while also receiving a Nasdaq non-compliance notice for its share price.
NASDAQ
CURX
Curanex Pharmaceuticals INC
10-Q: Curanex Pharmaceuticals Reports Q2 Losses, Secures IPO Funds
Curanex Pharmaceuticals Inc. reported increased net losses for Q2 2025 but successfully closed its IPO in August, raising $12.87 million to fund botanical drug development.